These results are preliminary data to support clinical trials for new NLRP3 inhibitors, anti-IL-1 and anti-IL-6 therapies or JAK 1⁄2 inhibitors in COVID-ARDS and in ARDS. Here, NLRP3 is linked to acute respiratory distress syndrome.